[Comparative studies of nafamostat mesilate and various serine protease inhibitors in vitro].
Inhibitory effects of nafamostat mesilate (nafamostat) on various enzymes were investigated, and they were compared with those of gabexate mesilate (gabexate), leupeptin, aprotinin and urinastatin in vitro. Nafamostat inhibited trypsin, plasmin, thrombin, pancreatic kallikrein, Clr and Cls more potently than gabexate and leupeptin. Gabexate and leupeptin did not inhibit pancreatic kallikrein and thrombin, respectively. Aprotinin inhibited trypsin, plasmin, pancreatic kallikrein and chymotrypsin. Urinastatin inhibited trypsin and chymotrypsin. Nafamostat inhibited the complement-mediated hemolysis in diluted serum more potently than gabexate and leupeptin, but aprotinin and urinastatin did not. Nafamostat, furthermore, inhibited the complement-mediated hemolysis in undiluted serum, but gabexate did not. Unlike aprotinin and urinastatin, nafamostat and gabexate inhibited alpha 2-macroglobulin bound trypsin as well as free trypsin to the same extent. The inhibitory effect of gabexate toward trypsin was reduced more markedly than that of nafamostat after incubation with plasma at 37 degrees C. These results show that nafamostat is more useful than other inhibitors such as gabexate, leupeptin, aprotinin and urinastatin.
D007611:Aprotinin / Q000494:pharmacology; D001550:Benzamidines; D003169:Complement Inactivator Proteins; D016670:Gabexate; D006023:Glycoproteins / Q000494:pharmacology; D006146:Guanidines / Q000494:pharmacology*; D006461:Hemolysis / Q000187:drug effects; D066298:In Vitro Techniques; D007976:Leupeptins / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology*; D011485:Protein Binding; D000511:alpha-Macroglobulins
D001550:Benzamidines; D003169:Complement Inactivator Proteins; D006023:Glycoproteins; D006146:Guanidines; D007976:Leupeptins; D011480:Protease Inhibitors; D000511:alpha-Macroglobulins; D016670:Gabexate; D007611:Aprotinin; C032854:leupeptin; C028665:urinastatin; C032855:nafamostat